Canterbury DHB
In the seven schedules, drug dosage is related either to the patient’s actual body weight or by calculating the Body Surface area (BSA). Any dose reduction due to renal dysfunction or obesity is done by the Haematology Pharmacist in conjunction with the Transplant Consultant. See also Cytotoxic Drugs in the Drug Usage section.
The dose of melphalan should be no greater than 3.6 mg/kg (see Costa et al, BJH (2008) 143, 268-273).
Day |
Time |
Medication |
-6 |
1000 |
Carmustine 300 mg/m2 |
-5 |
0830 |
Cytarabine 200 mg/m2 Q12H |
|
0900 |
Etoposide 200 mg/m2 |
|
2030 |
Cytarabine 200 mg/m2 Q12H |
-4 |
0830 |
Cytarabine 200 mg/m2 Q12H |
|
0900 |
Etoposide 200 mg/m2 |
|
2030 |
Cytarabine 200 mg/m2 Q12H |
-3 |
0830 |
Cytarabine 200 mg/m2 Q12H |
|
0900 |
Etoposide 200 mg/m2 |
|
2030 |
Cytarabine 200 mg/m2 Q12H |
-2 |
0830 |
Cytarabine 200 mg/m2 Q12H |
|
0900 |
Etoposide 200 mg/m2 |
|
2030 |
Cytarabine 200 mg/m2 Q12H |
-1 |
1000 |
Melphalan 140 mg/m2 |
0 |
24 hours following melphalan |
|
For more details, refer to:
|
Topic Code: 284004